Pain, Back, Pain, Chronic, Pain, Radiating
Conditions
Brief summary
This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain.
Detailed description
This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain. The trial length is 14 days. Patients will be given ultrahigh frequency pulse stimulation, up to 3 times in every 24 hours, and VAS will be obtained at least once a day. Compared to previous study conducted last year, patient can now have two lead implant sites for different pain locations. The electrode implantation site will be epidural space instead of Dorsal Root Ganglion (DRG).
Interventions
Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
Sponsors
China Medical University Hospital
GiMer Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≧20 and ≦75 2. Have a symptom of back or lower limb pain with a diagnosis related to spinal lesion, herniated disc, nerve injury, stenosis, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS) or ischemic lower limb pain and have pain history of \>6 months. 3. Have an average pain score \>5 by Visual Analogue Scale (VAS) on inclusion. 4. Has failed to achieve adequate pain relief from prior pharmacologic treatments. 5. In the judgement of the investigator, the subject is an appropriate candidate for the trial procedure. 6. The subject is willing and able to comply with the procedure and requirements of this trial. 7. The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with Institutional Review Board (IRB) requirements.
Exclusion criteria
1. Have evidence of a mental or psychological condition that affects pain perception and has difficulty/disability performing objective pain assessment, or have previously failed mental or psychological assessments administered by a psychiatrist that may be deemed to indicate the subject's lack of suitability for participation in this study. 2. Subject has exhibited unstable pain condition within the past 30 days as interviewed by Investigator. 3. Be on anticoagulant medication with International Normalized Ratio (INR) \>1.5 or platelet count less than 100,000/μL, peripheral vascular diseases (PVDs), visceral pain or uncontrolled Diabetes mellitus (DM). 4. Has had corticosteroid therapy at an intended site of stimulation within the past 30 days. 5. Pain medication(s) dosages(s) are not stable for at least 30 days at investigator's discretion. 6. Currently has an active implantable device including International Classification of Diseases (ICD), pacemaker, spinal cord stimulator or intrathecal drug pump or subject requires magnetic resonance imaging (MRIs) or diathermy. 7. Have a current diagnosis of cancer with active symptoms. 8. Have a known terminal illness with life expectancy less than one year. 9. Have a systematic or local infection, which may increase study risk. 10. Currently has an indwelling device that may pose an increased risk of infection. 11. Be pregnant or breast feeding. 12. Have a medical history of drug or alcohol addiction within the past 2 years. 13. Participation in any investigational study in the last 30 days or current enrollment in any trial. 14. Be currently involved in an injury claim law suit or medically related litigation, including workers compensation. 15. Be a prisoner.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Visual Analog Score From Baseline to Day 14 | 14 days | To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline. |
| Record Incidence of Adverse Events | 14 days | To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Brief Pain Inventory (BPI) | 14 days | The change from baseline in functionality using the BPI evaluations |
| Incidence of Stimulation-induced Paresthesia | 14 days | To determine the presence or absence of stimulation-induced paresthesia. |
| Pain Relief Medication Consumption | 14 days | Amount of pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline |
| Oswestry Low Back Pain Disability Questionnaire (ODI) | 14 days | The change from baseline in functionality using the ODI evaluations |
Countries
Taiwan
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ultrahigh Frequency (500 KHz) Stimulation This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
GiMer Medical MN 1000 External Stimulator: Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Ultrahigh Frequency (500 KHz) Stimulation | — |
|---|---|---|
| Age, Continuous | 43.5 years | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Sex: Female, Male Female | 5 Participants | — |
| Sex: Female, Male Male | 5 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 10 |
| other Total, other adverse events | 9 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Change in Visual Analog Score From Baseline to Day 14
To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline.
Time frame: 14 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ultrahigh Frequency (500 KHz) Stimulation | Change in Visual Analog Score From Baseline to Day 14 | -5.1 score on a scale | Standard Deviation 2.3 |
Primary
Record Incidence of Adverse Events
To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial
Time frame: 14 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ultrahigh Frequency (500 KHz) Stimulation | Record Incidence of Adverse Events | 16 events |
Secondary
Incidence of Stimulation-induced Paresthesia
To determine the presence or absence of stimulation-induced paresthesia.
Time frame: 14 days
Secondary
Oswestry Low Back Pain Disability Questionnaire (ODI)
The change from baseline in functionality using the ODI evaluations
Time frame: 14 days
Secondary
Pain Relief Medication Consumption
Amount of pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline
Time frame: 14 days
Secondary
The Brief Pain Inventory (BPI)
The change from baseline in functionality using the BPI evaluations
Time frame: 14 days